Business
Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer
Mr. Healey is a seasoned pharmaceutical executive with a strong track record of successful commercial leadership experienceCHAPEL HILL, N.C., May 04, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, announced today the appointment of Timothy Healey, MBA, as Chief Commercial Officer (CCO), effective immediately.
About this update from Tenax Therapeutics, Inc.
[{"type":"image","alt":"Tenax Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Tenax Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":114,"url":"https://media.zenfs.com/en/globenewswire.com/db9e802274359b8735193ba3952d6da1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/NyhLOWhEnJXss8x2xP1RwQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2MA--/https://media.zenfs.com/en/globenewswire.com/db9e802274359b8735193ba3952d6da1","width":300,"height":114}},"lazy":false},{"type":"text","content":"Mr. Healey is a seasoned pharmaceutical executive with a strong track record of successful commercial leadership experience","length":123,"tagName":"p"},{"type":"text","content":"CHAPEL HILL, N.C., May 04, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, announced today the appointment of Timothy Healey, MBA, as Chief Commercial Officer (CCO), effective immediately. Mr. Healey is a proven commercial leader who has led several successful drug launches and joins Tenax to oversee its global commercial strategy.","length":522,"tagName":"p"},{"type":"text","content":"“Tim is a transformational commercial leader with a proven ability to translate complex science into successful product launches,” said Chris Giordano, President and Chief Executive Officer of Tenax Therapeutics. “Tim’s expertise as an innovative commercial strategist, combined with his history of strong launch execution, makes him uniquely suited to lead Tenax’s commercial organization. In his new role, Tim will be responsible for preparing Tenax and TNX-103 for commercial success, including the development of processes, capabilities, and support required to execute a successful commercial launch.”","length":606,"tagName":"p"},{"type":"text","content":"“I am thrilled to join the Tenax team at such a dynamic moment in the company’s history,” said Mr. Healey. “Tenax’s commitment to innovation, scientific excellence, and patient outcomes is inspiring, and I look forward to working with this talented team to help ensure our innovations reach the patients who need them.”","length":319,"tagName":"p"},{"type":"text","content":"Mr. Healey is a seasoned pharmaceutical exec...